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Abstract
Recent studies suggest that differences in antifungal activity among echinocandins may exist. In this study, the activities of three echino-
candins (anidulafungin, caspofungin, and micafungin) against Candida parapsilosis isolates from burn unit patients, healthcare workers and
the hospital environment were determined. Additionally, the effect of these echinocandins on the cell morphology of caspofungin-sus-
ceptible and caspofungin-non-susceptible isolates was assessed using scanning electron microscopy (SEM). The C. parapsilosis isolates
obtained from patients were susceptible to anidulafungin, but were less so to caspofungin and micafungin. Isolates obtained from health-
care workers or environmental sources were susceptible to all antifungals. SEM data demonstrated that although anidulafungin and
caspofungin were equally active against a caspofungin-susceptible C. parapsilosis strain, they differed in their ability to damage a caspofun-
gin-non-susceptible strain, for which lower concentrations of anidulafungin (1 mg/L) than of caspofungin (16 mg/L) were needed to
induce cellular damage and distortion of the cellular morphology. To determine whether the difference in the antifungal susceptibility of
C. parapsilosis isolates to anidulafungin as compared to the other two echinocandins could be due to different mutations in the FKS1
gene, the sequences of the 493-bp region of this gene associated with echinocandin resistance were compared. No differences in the
corresponding amino acid sequences were observed, indicating that differences in activity between anidulafungin and the other echino-
candins are not related to mutations in this region. The results of this study provide evidence that differences exist between the activi-
ties of anidulafungin and the other echinocandins.
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Candida species represent the fourth most common cause of
nosocomial bloodstream infections [1]. Approximately half of
the cases of candidaemia are due to non-albicans species, such
as Candida glabrata, Candida parapsilosis and Candida tropicalis
[1–3]. Among the non-albicans spp., C. parapsilosis is associated
with bloodstream infections, particularly in patients with
indwelling catheters and prosthetic devices, including critically
ill patients in neonatal units and intensive-care units (ICUs) [4–7],
patients undergoing peritoneal dialysis, and patients with pros-
thetic heart valves [8–15]. The echinocandins and the triazoles
have become the mainstay of antifungal therapy for the treat-
ment of mucosal and systemic fungal infections [16–18]. Over-
all, echinocandins demonstrate reduced in vitro activity against
C. parapsilosis when compared to other Candida spp., and
recent studies have reported the rare development of resis-
tance to caspofungin and micafungin [19–23]. Moudgal et al.
[19] reported the isolation of multi-echinocandin-resistant
and multi-azole-resistant strains of C. parapsilosis that were
serially recovered from a patient with prosthetic valve endo-
carditis after being treated with caspofungin and ﬂuconazole.
Of importance was the reduced activity of caspofungin and
micafungin in sequential isolates, while anidulafungin activity
remained unchanged. Although the mechanism of action of
the echinocandins is similar, it is likely that differences exist in
antifungal activity among the three echinocandins and also
among the fungal resistance mechanisms.
To evaluate this possibility, C. parapsilosis isolates obtained
from burn unit patients, healthcare workers (HCWs) and the
environment of the burn unit in a large tertiary-care teaching
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hospital in Detroit, MI were characterized. These studies
showed anidulafungin to be different from caspofungin and
micafungin in its antifungal activity against C. parapsilosis.
Materials and Methods
Candida strains
The C. parapsilosis isolates evaluated in this study were
recovered from patients, HCWs, and environmental sources
in a tertiary-care burn ICU. Patients were prospectively fol-
lowed during hospitalization in the burn unit from June to
November 2004. Samples were collected from each patient
from non-sterile sites. Candida species recovered from the
bloodstream during the study period were also collected.
Samples from the hands of HCWs in the burn unit were
obtained using the ‘hand-washing’ technique as described
previously [24]. Environmental samples from various loca-
tions in the unit were collected using replicate organism
detection and counting plates (RODAC; BD Diagnostics Sys-
tems, Franklin Lakes, NJ, USA) as previously described [25].
During the study period, both caspofungin and ﬂuconazole
were commonly used as empirical therapy or for the treat-
ment of documented fungal infections. All yeasts were identi-
ﬁed to the species level using the germ-tube test and
chlamydospore formation, and were conﬁrmed using the
API 32C kit (bioMerieux Inc., Durham, NC, USA) [26]. Only
strains that were found to differ, according to pulsed-ﬁeld
gel electrophoresis, from isolates from either the same
patient or from different patients were included in the study.
In addition, reference strains (obtained from the American
Type Culture Collection (ATCC)) of C. parapsilosis, Candida
orthopsilosis and Candida metapsilosis were included as control
strains (ATCC 96139, ATCC 96143 and ATCC 22019,
respectively).
Antifungal susceptibility
The in vitro susceptibilities of C. parapsilosis isolates obtained
from patients, HCWs and the burn unit environment were
determined according to the guidelines of the CLSI as
described in the M27-A2 microdilution method for yeasts
[27]. Recently, the CLSI Antifungal Subcommittee has recom-
mended a susceptibility breakpoint of £2 mg/L for anidulafun-
gin, caspofungin and micafungin, while designating all isolates
with an MIC >2 mg/L as non-susceptible [28].
Genotyping
Genotyping of C. parapsilosis strains was performed by karyo-
typing using CHEF elctrophoresis as described previously
[19].
Scanning electron microscopy (SEM)
The effects of anidulafungin and caspofungin on the ultrastruc-
ture and cell morphology of two C. parapsilosis isolates (one
caspofungin-susceptible and the other caspofungin-non-sus-
ceptible) were evaluated using SEM. Yeast cells were grown in
the presence of different concentrations of either anidulafun-
gin or caspofungin, and processed for SEM as described previ-
ously [29]. Samples were sputter-coated with Au/Pd (60 : 40)
and viewed with an ESEM (model XL3C Philips) scanning elec-
tron microscope (Philips Research, Eindhoven, The Nether-
lands), using a voltage of 15 kV and a spot size of 4¢¢.
DNA sequence analysis of FKS1
To determine whether differences in echinocandin susceptibil-
ities were due to mutations in the hot spot region of FKS1
(which has been associated with development of echinocandin
resistance) [30–32], DNA sequence analysis of this region was
performed. A 493-bp portion of FKS1 was ampliﬁed, using
PCR and Candida albicans primers F1719 and R2212, and
sequenced using the same primers as previously described
[22,23] (Park S, Paderu P, Perlin DS. 46th InterScience Con-
ference on Antimicrobial Agents and Chemotherapy, Abstract
M-1755. San Francisco, CA: American Society for Microbiol-
ogy, 2006). Sequences of the ampliﬁed segments were aligned
and compared using the Blast program.
Results
Isolation of Candida strains
During the 6-month study period, 22 patients were
prospectively followed during their stay in the burn unit. Can-
dida isolates were recovered from 18 of the 22 patients and
from multiple non-sterile sites (oropharynx, female genital
tract, perineum and wound). Among the 18 patients, 11
(61%) were colonized with C. parapsilosis, and seven (39%)
were colonized with C. albicans. In total, 59 C. parapsilosis iso-
lates were recovered from these 11 patients. Samples were
obtained from 24 HCWs, of whom ten (42%) had Candida
spp. From these ten HCWs, C. parapsilosis was recovered in
seven cases (70%), whereas the rest were colonized with
C. albicans. Environmental sampling resulted in the isolation of
three C. parapsilosis strains. Overall, 69 C. parapsilosis isolates
(59 from burn unit patients, seven from HCWs, and three
from the environment) and 11 C. albicans isolates (seven from
patients and four from HCWs) were obtained. However, 33
C. parapsilosis isolates were identiﬁed as different strain types
after CHEF electrophoresis, and were used in the ﬁnal analy-
sis. These organisms consisted of 23 isolates from patients,
seven isolates from HCWs, and three isolates from the
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environment. In this study, analysis of the C. parapsilosis iso-
lates was the focus.
Antifungal susceptibility testing
Table 1 summarizes the susceptibility patterns of the 23
C. parapsilosis isolates obtained from burn patients.
When caspofungin and micafungin were tested against
these C. parapsilosis isolates, elevated MIC90 values were
found (8 and 16 mg/L, respectively), whereas the MIC90 value
for anidulafungin was four-fold to eight-fold lower
(MIC90 2 mg/L, Table 1).
These results indicated that anidulafungin had more potent
antifungal activity than the other two candins against the
C. parapsilosis isolates tested.
The antifungal susceptibilities of the C. parapsilosis isolates
obtained from the hands of HCWs and the burn unit envi-
ronment are shown in Table 2. Whereas C. parapsilosis iso-
lates were susceptible to anidulafungin and caspofungin (with
MIC50 and MIC90 values of 1 mg/L for both), they tended to
be non-susceptible to micafungin (MIC50 and MIC90 of 8 mg/
L for both).
Strain differentiation
Strain differentiation of all the 59 C. parapsilosis isolates
recovered from 11 burn patients revealed 23 different strain
types (Fig. 1). Eighteen per cent of the patients had the same
strain throughout their entire stay in the burn unit. In addi-
tion, 71% of C. parapsilosis strains obtained from HCWs
were similar to the strains recovered from several patients
(data not shown). Moreover, two of the three environmental
C. parapsilosis isolates were also similar to those recovered
from HCWs and patients. These results provide evidence to
conﬁrm the transmission of clinical C. parapsilosis isolates
between the environment, HCWs and patients.
SEM analysis
The ability of caspofungin and anidulafungin to affect the
ultrastructure of C. parapsilosis was evaluated in two isolates
(one caspofungin-susceptible and one caspofungin-non-sus-
ceptible) by SEM. As shown in Fig. 2, untreated C. parapsilosis
cells showed normal yeast ultrastructure with smooth cell
morphology (Fig. 2a,d). In contrast, treatment of the caspo-
fungin-susceptible strain with anidulafungin or caspofungin
affected the cell morphology dramatically, resulting in cell
collapse and deformity, and leakage of cytoplasmic material
that ultimately led to cell damage and lysis (Fig. 2b,c, respec-
tively).
This uniformity of activity between anidulafungin and
caspofungin did not extend to the caspofungin-non-suscepti-
ble C. parapsilosis strain, where differences in their effects
were noted. In this regard, exposure of the caspofungin-non-
susceptible C. parapsilosis strain to 2 mg/L anidulafungin led
to cell swelling, lysis and collapse (Fig. 2e), whereas caspofun-
gin at the same concentration (2 mg/L) had no effect on the
morphology of this strain (data not shown). For caspofungin
to exert a signiﬁcant effect on the morphology of the C. par-
apsilosis caspofungin-non-susceptible strain, it was necessary
to increase the concentration to 16 mg/L (Fig. 2f). These
SEM results demonstrated that anidulafungin and caspofungin
TABLE 1. Antifungal susceptibilities of 23 Candida parapsi-
losis isolates recovered from burn unit patients
Caspofungin Micafungin Anidulafungin
MIC50 1 8 1
MIC90 8 16 2
MIC range 0.125–8 0.03–16 0.03–2
MIC50 and MIC90 (mg/L) represent the minimum drug concentration that
inhibits 50% and 90% of isolates tested, respectively.
TABLE 2. Antifungal susceptibilities of ten Candida parapsi-
losis isolates recovered from the hands of healthcare
workers and burn unit environmental surfaces
Caspofungin Micafungin Anidulafungin
MIC50 1 8 1
MIC90 1 8 1
MIC range 0.5–2 0.5–8 0.5–2
MIC50 and MIC90 (mg/L) represent the minimum drug concentration that
inhibits 50% and 90% of isolates tested, respectively.
FIG. 1. Electrophoretic karyotype of Candida parapsilosis isolates
recovered from eight different patients. Lanes A and B: controls.
Lanes C–J: patient isolates.
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possess equivalent activity against the caspofungin-susceptible
C. parapsilosis strain. However, they differ in their ability to
damage the C. parapsilosis caspofungin-non-susceptible strain:
lower concentrations of anidulafungin than of caspofungin
were sufﬁcient to induce cellular damage and to distort the
cellular morphology of this strain.
FKS1 sequence analysis
To determine whether the difference in the antifungal sus-
ceptibility of C. parapsilosis isolates to anidulafungin as com-
pared to the other two echinocandins could be due to
different mutations in FKS1, the sequence of the 493 bp
region of this gene was determined in eight isolates.
Blast search analysis of the sequenced FKS1 region
revealed 94% identity with that of the C. albicans 1,3-b-D-
glucan synthase gene. Alignment of the deduced amino acid
sequences from two susceptible C. parapsilosis isolates and
six non-susceptible isolates did not reveal any differences
in the amino acid patterns within the previously reported
‘‘hot spot’’ regions [30–32].
Discussion
In this study, differential echinocandin activity against C. par-
apsilosis isolates recovered from patients in a burn ICU was
investigated for the ﬁrst time. These unique isolates exhib-
ited non-susceptibility to caspofungin and micafungin, while
remaining susceptible to anidulafungin.
The data conﬁrm and extend the ﬁndings of Moudgal et al.
[19], who reported isolation of sequential multi-echinocan-
din-resistant C. parapsilosis isolates from a patient during
therapy for prosthetic valve endocarditis. The C. parapsilosis
isolates studied here and those of Moudgal et al. demon-
strated that although they had reduced susceptibility to ca-
spofungin and micafungin (elevated MIC90 of both agents),
they remained susceptible to anidulafungin (low MIC90).
SEM was performed to determine whether the observed
differences in antifungal susceptibility of the C. parapsilosis
isolates to anidulafungin and caspofungin are reﬂected in the
effect of these echinocandins at the morphological level. This
analysis showed that a much lower concentration of anidula-
fungin (1 mg/L) than of caspofungin (16 mg/L) was needed to
cause a dramatic effect on cell morphology in the caspofun-
gin-non-susceptible C. parapsilosis isolates. These ﬁndings pro-
vide further evidence that differences exist among the three
echinocandins; that is, caspofungin and micafungin behave
similarly, but differently from anidulafungin.
The difference between anidulafungin and the other two
echinocandins regarding antifungal susceptibility has also been
demonstrated recently in C. tropicalis by Pasquale et al. [33].
These authors reported the case of a 28-year-old female
with acute myelogenous leukaemia, fever, otitis media and
invasive candidal oesophagitis. Treatment with caspofungin
was initiated, but therapy failed after 5 days. In vitro echino-
candin susceptibility testing of the C. tropicalis isolate showed
MICs of anidulafungin, caspofungin and micafungin of 1.0, 4.0
and 8.0 mg/L, respectively. Similar to the present ﬁndings,
(a) (b) (c)
(d) (e) (f)
FIG. 2. Effect of anidulafungin (ANID) and caspofungin (CASPO) on surface structure and morphology of (a–c) caspofungin-susceptible or (d–f)
caspofungin-non-susceptible C. parapsilosis isolates. The susceptible C. parapsilosis isolate was exposed to: (a) no drug (control); (b) anidulafungin,
0.25 mg/L; or (c) caspofungin, 0.25 mg/L. The non-susceptible C. parapsilosis isolate was exposed to: (d) no drug; (e) anidulafungin, 2 mg/L; or (f)
caspofungin, 16 mg/L. Bars represent 5 lm in (a)–(e) and 10 lm in (f). Magniﬁcation: ·8000 (a), and ·5000 (b–f).
CMI Ghannoum et al. Characterization of C. parapsilosis 277
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 274–279
these investigators found cross-resistance between caspofun-
gin and micafungin in the isolated C. tropicalis species.
Resistance of C. albicans isolates to caspofungin was
recently reported by Laverdiere et al. [34], who showed a
progressive increase in MICs of different echinocandins for
four sequential C. albicans isolates obtained from a human
immunodeﬁciency virus-infected patient with chronic oesoph-
agitis. These isolates exhibited progressive resistance to
micafungin following prolonged treatment, and showed
increased caspofungin and anidulafungin MICs, indicating
reduced susceptibility to all three echinocandins. Thus, unlike
the present results with C. parapsilosis, where cross-resis-
tance between micafungin and caspofungin does not extend
to anidulafungin, in C. albicans, cross-resistance may span
all three echinocandins, suggesting that cross-resistance to
echinocandins may be species-dependent.
Additionally, an interesting result was that non-susceptibil-
ity was only seen in the C. parapsilosis isolates obtained from
patients in the burn unit, and not in those obtained from the
hands of HCWs or the environmental samples. Although the
reason for this reduced susceptibility to caspofungin and mi-
cafungin in C. parapsilosis isolates obtained from burn unit
patients is unknown, possible explanations include the
following: (i) when C. parapsilosis is exposed to the host
environment, it may adapt by expressing genes that aid in its
survival; and (ii) all of these isolates were recovered from a
busy tertiary-care burn unit with high rates of candidaemia
and candidiasis, and with usage rates for both ﬂuconazole
and caspofungin that are extremely high when compared to
other parts of the hospital. These factors exert signiﬁcant
selective pressure on Candida.
The mechanism(s) underlying the reduced susceptibility
of C. parapsilosis to caspofungin and micafungin, but not to
anidulafungin, is unknown. Several studies suggest that amino
acid substitutions in two short regions of the FKS1 gene (hot
spots 1 and 2) represent a universal mechanism of resistance
to echinocandins in yeast and moulds [30,32,34,35] (Park S,
Paderu P, Perlin DS. 46th InterScience Conference on Anti-
microbial Agents and Chemotherapy, Abstract M-1755. San
Francisco, CA: American Society for Microbiology, 2006.).
The present data did not reveal amino acid changes in the
known FKS1 hot spots reported previously, indicating that
the difference in susceptibility of C. parapsilosis is not due to
mutations in this region. In this regard, Hakki et al. [36]
described a case of Candida krusei infection that progressed
despite caspofungin therapy, and showed that reduced echi-
nocandin susceptibility of this isolate was not associated with
mutations in FKS1. It is possible that mutations in FKS2 and
FKS3 may be responsible for the differences in the echino-
candin susceptibility observed. The current study did not
evaluate mutations in the corresponding genes. Alternatively,
it is possible that although all echinocandins target the same
enzyme (1,3-b-D-glucan synthase), differences in the afﬁnity
of the enzyme for these agents may exist, possibly due to
variations in the drugs’ molecular structures. This scenario is
not unique to the echinocandins, as differential activity pat-
terns have been shown among the different members of the
azole class of antifungals [36,37].
In conclusion, these results provide evidence of differential
anti-C. parapsilosis activities of anidulafungin and of caspofun-
gin and micafungin. Moreover, the data show that the differ-
ences in the activity of the three echinocandins against the
C. parapsilosis isolates tested are not related to mutations in
FKS1. The clinical implications of these ﬁndings are yet to be
determined.
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